Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and glucagon-like peptide 2

lapatinib has been researched along with glucagon-like peptide 2 in 1 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(glucagon-like peptide 2)		Trials
(glucagon-like peptide 2)		Recent Studies (post-2010) (glucagon-like peptide 2)
1,9193051,44279864442

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bateman, E; Bowen, JM; Keefe, DM; Mayo, BJ; Pietra, C; Secombe, KR; Thorpe, D; Wignall, AD1

Other Studies

1 other study(ies) available for lapatinib and glucagon-like peptide 2

ArticleYear
The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:4

    Topics: Animals; Antidiarrheals; Diarrhea; Glucagon-Like Peptide 2; Intestinal Mucosa; Lapatinib; Male; Protein Kinase Inhibitors; Rats; Rats, Wistar

2020